Related Experiment Video
Updated: Mar 16, 2026
06:33
Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis
Published on: June 9, 2018
8.2K
α1-Antitrypsin Deficiency
Umur Hatipoğlu1, James K Stoller2
1Respiratory Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk A-90, Cleveland, OH 44195, USA.
Clinics in Chest Medicine
|August 13, 2016
Summary
Alpha-1 antitrypsin deficiency is an under-recognized genetic condition leading to emphysema and cirrhosis. Augmentation therapy shows promise in slowing emphysema progression in severe cases.
Area of Science:
- Genetics
- Pulmonology
- Hepatology
Background:
- Alpha-1 antitrypsin deficiency is an autosomal codominant disorder.
- It is a significant risk factor for developing emphysema and cirrhosis.
- The condition is prevalent yet frequently undiagnosed.
Purpose of the Study:
- To highlight the importance of identifying alpha-1 antitrypsin deficiency.
- To discuss the implications for patient management and treatment.
- To review evidence supporting augmentation therapy.
Main Methods:
- Literature review on alpha-1 antitrypsin deficiency.
- Analysis of management strategies.
- Evaluation of augmentation therapy efficacy.
Main Results:
- Early identification enables crucial interventions like smoking cessation and counseling.
- Augmentation therapy involves infusing pooled human plasma alpha-1 antitrypsin.
- Evidence supports that augmentation therapy can slow emphysema progression.
Conclusions:
- Prompt diagnosis of alpha-1 antitrypsin deficiency is critical for patient outcomes.
- Management includes lifestyle changes and specific augmentation treatments.
- Augmentation therapy offers a therapeutic option for severe alpha-1 antitrypsin deficiency.
Keywords:
Augmentation therapyCirrhosisDiagnostic testingEmphysemaTargeted detectionα(1)-Antitrypsin deficiencyMore Related Videos
Related Concept Videos
01:20Inborn Errors of Metabolism
986
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
986
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
5.0K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
5.0K
01:24Cystic Fibrosis: Management
605
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
605
01:23Cystic Fibrosis: Pathogenesis
1.0K
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
1.0K
01:22Lysosomal Hydrolases
4.7K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.7K
01:20Myasthenia Gravis: Overview and Treatment
3.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.3K